Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | SNCA | P37840 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | FUT7 | Q11130 | 2/20 | 0.42 |
| ▸ | SELL | P14151 | 2/20 | 0.42 |
| ▸ | SELP | P16109 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | FUT4 | P22083 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4170160 | 0.98 | KDM4E (0.41) | KDM4ELMNATDP1SNCAALDH1A1 | |
| SCHEMBL13924923 | 0.82 | PTGS2 (0.55) | KDM4ELMNATDP1FUT7CA12 | |
| SCHEMBL12348318 | 0.81 | HDAC8 (0.30) | HDAC6 | |
| SCHEMBL3237538 | 0.78 | TTR (0.48) | LMNATDP1ALDH1A1MAPTCA1 | |
| SCHEMBL261652 | 0.76 | CA1 (0.44) | ALDH1A1CA1CA2GAAL3MBTL1 | |
| SCHEMBL6377504 | 0.76 | HDAC6 (0.57) | KDM4ESNCAMAPTCA12CA1 | |
| SCHEMBL8121970 | 0.76 | TTR (0.46) | KDM4ELMNAALDH1A1MAPTHPGD | |
| SCHEMBL20580082 | 0.72 | SNCA (0.46) | KDM4ELMNASNCAHSD17B10HDAC6 | |
| SCHEMBL261538 | 0.72 | GABRA1 (0.40) | ALDH1A1 | |
| SCHEMBL131601 | 0.70 | KDM4E (0.64) | KDM4ELMNATDP1SNCAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1053012-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | ENZON PHARMACEUTICALS INC (US) | 2003-07-23 | — | — | EP | claimed |
| WO-2001010454-A9 | PHARMACEUTICAL COMPOSITION COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTION | AVENTIS PHARM PROD INC (US) | 2002-11-07 | — | — | WO | claimed |
| EP-1143990-A3 | PHARMACEUTICAL COMPOSTIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | Aventis Pharmaceuticals Inc. (US) | 2002-03-27 | — | — | EP | claimed |
| EP-1143990-A2 | PHARMACEUTICAL COMPOSTIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | Aventis Pharmaceuticals Inc. (US) | 2001-10-17 | — | — | EP | claimed |
| US-6248782-B1 | ADMINISTERING ENZYME INHIBITOR | ELFORD HOWARD L (US) | 2001-06-19 | — | — | US | claimed |
| WO-2001010454-A2 | PHARMACEUTICAL COMPOSITION COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTION | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2001-02-15 | — | — | WO | claimed |
| EP-1053012-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-22 | — | — | EP | claimed |
| WO-1999039732-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-08-12 | — | — | WO | claimed |
| EP-0610444-A4 | METHOD OF TREATING VIRAL DISEASES. | ELFORD HOWARD L (US) | 1995-05-17 | — | — | EP | claimed |
| EP-0610444-A1 | METHOD OF TREATING VIRAL DISEASES | ELFORD, Howard L. (US) | 1994-08-17 | — | — | EP | claimed |
| WO-1993012782-A1 | METHOD OF TREATING VIRAL DISEASES | ELFORD HOWARD L (US) | 1993-07-08 | — | — | WO | claimed |
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2017-04-13 | — | — | US | disclosed |
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2017-04-13 | — | — | US | disclosed |
| US-9526707-B2 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526707-B2 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2016-12-27 | — | — | US | disclosed |
| WO-1999048526-A1 | METHOD OF RENDERING A HUMAN IMMUNODEFICIENCY VIRUS POPULATION REPLICATION INCOMPETENT $i(IN VIVO) | LORI FRANCO (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999047146-A1 | ANTI-HIV COMBINATION COMPRISING HYDROXYUREA, DDI, AND A PROTEASE INHIBITOR | LISZIWIEWICZ JULIANNA (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999039732-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-08-12 | — | — | WO | disclosed |
| EP-0706387-A1 | NEW PROCEDURE TO BLOCK THE REPLICATION OF REVERSE TRANSCRIPTASE DEPENDENT VIRUSES BY THE USE OF INHIBITORS OF DEOXYNUCLEOTIDES SYNTHESIS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-04-17 | — | — | EP | disclosed |
| WO-1994027590-A1 | NEW PROCEDURE TO BLOCK THE REPLICATION OF REVERSE TRANSCRIPTASE DEPENDENT VIRUSES BY THE USE OF INHIBITORS OF DEOXYNUCLEOTIDES SYNTHESIS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | KDM4E 3319/4885LMNA 2888/4885TDP1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.